Literature DB >> 15639107

Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.

Rodger L Bick1, Eugene P Frenkel, Jeanine Walenga, Jawed Fareed, Deborah A Hoppensteadt.   

Abstract

During the past decade, a large number of new anticoagulant and antithrombotic drugs have been developed. These agents represent a wide variety of substances that are derived using natural sources, biotechnology-based methods, and synthetic approaches. Because of the structural and molecular characteristics, these agents exhibit physicochemical and functional diversities. Thus, each of these classes of drugs controls thrombogenesis by way of distinct mechanisms. The main classes of these new drugs include peptides, peptidomimetics, heparinomimetics, and recombinant proteins. Despite these significant developments, heparin and heparin-derived drugs have continued to play a major role in the management of thrombotic and cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15639107     DOI: 10.1016/j.hoc.2004.09.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  20 in total

1.  Structural characterization of heparins from different commercial sources.

Authors:  Fuming Zhang; Bo Yang; Mellisa Ly; Kemal Solakyildirim; Zhongping Xiao; Zhenyu Wang; Julie M Beaudet; Amanda Y Torelli; Jonathan S Dordick; Robert J Linhardt
Journal:  Anal Bioanal Chem       Date:  2011-09-20       Impact factor: 4.142

2.  Analysis of 3-O-sulfo group-containing heparin tetrasaccharides in heparin by liquid chromatography-mass spectrometry.

Authors:  Guoyun Li; Bo Yang; Lingyun Li; Fuming Zhang; Changhu Xue; Robert J Linhardt
Journal:  Anal Biochem       Date:  2014-03-28       Impact factor: 3.365

3.  Structure and activity of a new low-molecular-weight heparin produced by enzymatic ultrafiltration.

Authors:  Li Fu; Fuming Zhang; Guoyun Li; Akihiro Onishi; Ujjwal Bhaskar; Peilong Sun; Robert J Linhardt
Journal:  J Pharm Sci       Date:  2014-03-14       Impact factor: 3.534

4.  Surprising absence of heparin in the intestinal mucosa of baby pigs.

Authors:  Yanlei Yu; Yin Chen; Paiyz Mikael; Fuming Zhang; Apryll M Stalcup; Rebecca German; Francois Gould; Jocelyn Ohlemacher; Hong Zhang; Robert J Linhardt
Journal:  Glycobiology       Date:  2016-10-15       Impact factor: 4.313

Review 5.  [Prophylaxis of venous thromboembolic events in head and neck surgery].

Authors:  B Höing; U W Geisthoff; C E Dempfle; S Lang; B A Stuck
Journal:  HNO       Date:  2017-11       Impact factor: 1.284

6.  Mitigation of device-associated thrombosis and thromboembolism using combinations of heparin and tirofiban.

Authors:  Stacy Meola; Gregory Burns; Sivaprasad Sukavaneshvar; Kenneth Solen; Syed Mohammad
Journal:  J Extra Corpor Technol       Date:  2006-09

Review 7.  New options with dabigatran etexilate in anticoagulant therapy.

Authors:  Lars Maegdefessel; Joshua M Spin; Junya Azuma; Philip S Tsao
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

Review 8.  Heparin and related polysaccharides: synthesis using recombinant enzymes and metabolic engineering.

Authors:  Matthew Suflita; Li Fu; Wenqin He; Mattheos Koffas; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2015-07-29       Impact factor: 4.813

Review 9.  Lessons learned from the contamination of heparin.

Authors:  Haiying Liu; Zhenqing Zhang; Robert J Linhardt
Journal:  Nat Prod Rep       Date:  2009-01-19       Impact factor: 13.423

Review 10.  Bioengineered heparins and heparan sulfates.

Authors:  Li Fu; Matthew Suflita; Robert J Linhardt
Journal:  Adv Drug Deliv Rev       Date:  2015-11-10       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.